Digestive & Intestinal Remedies (Pharmacies) - NAFTA

Revenue in the Digestives & Intestinal Remedies market is projected to reach US$1.48bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 1.49%, resulting in a market volume of US$1.59bn by 2029.
In global comparison, most revenue will be generated China (US$3.37bn in 2024).
In relation to total population figures, per person revenues of US$2.90 are generated in 2024.

Definition:
The Digestives and Intestinal Remedies market encompasses a range of over-the-counter (OTC) natural and synthetic digestive agents and remedies designed to address gastrointestinal concerns. These products are available through pharmacies and are provided in various forms such as pills, powder, capsules, liquids, solutions, suspensions, drops, and suppositories. The market excludes prescription medications, substances contravening state regulations, or items not explicitly categorized as digestive medications (e.g., pain relievers). Notable among the best-selling products in this category are Perenterol, Iberogast, Dulcolax, and Buscopan Plus. This market exclusively covers product sales through pharmacies.

Additional information:
The Digestives and Intestinal Remedies market comprises revenues, average revenue per capita and average revenue per pharmacy. Revenues include VAT. The market only displays B2C revenues, hence B2B and B2G revenues are not included.
For more information on the data displayed, use the info button next to the boxes.

Natural and synthetic agents
Digestive medicines
Remedies against gastrointestinal complaints

Prescription medicines
Homeopathic remedies
Tea

The Digestive & Intestinal Remedies (Pharmacies) market in NAFTA is experiencing steady growth due to changing customer preferences and underlying macroeconomic factors. Customer preferences in the Digestive & Intestinal Remedies market have shifted towards natural and herbal remedies, as consumers become more health-conscious and seek products with fewer side effects. This trend is driven by a growing awareness of the benefits of natural ingredients and a desire for more holistic approaches to healthcare. Additionally, consumers are increasingly seeking convenience in their healthcare choices, leading to a rise in demand for over-the-counter remedies that can be easily purchased at pharmacies. Trends in the market include the growing popularity of probiotics and digestive enzymes as consumers recognize their potential to improve gut health. Probiotics, in particular, have gained traction as they are believed to promote a healthy balance of bacteria in the gut, leading to improved digestion and overall well-being. This trend is further fueled by the increasing prevalence of digestive disorders such as irritable bowel syndrome and acid reflux, which has created a larger consumer base for Digestive & Intestinal Remedies. Local special circumstances within the NAFTA region also contribute to the growth of the Digestive & Intestinal Remedies market. In the United States, for example, the high prevalence of fast food consumption and sedentary lifestyles has led to an increase in digestive health issues, driving demand for remedies. In Canada, an aging population and rising healthcare costs have prompted individuals to take a more proactive approach to their health, leading to increased sales of Digestive & Intestinal Remedies. In Mexico, the market is driven by a combination of factors including a growing middle class, increasing consumer awareness, and a strong tradition of natural remedies. Underlying macroeconomic factors, such as GDP growth and disposable income, also play a role in the development of the Digestive & Intestinal Remedies market in NAFTA. As economies in the region continue to grow, consumers have more purchasing power and are willing to spend on healthcare products that improve their quality of life. Additionally, the increasing prevalence of digestive health issues and the rising cost of prescription medications have led consumers to seek affordable alternatives, further driving the demand for Digestive & Intestinal Remedies. Overall, the Digestive & Intestinal Remedies (Pharmacies) market in NAFTA is experiencing growth due to changing customer preferences towards natural remedies, increasing awareness of digestive health issues, and underlying macroeconomic factors. As consumers continue to prioritize their health and seek convenient and affordable solutions, the market is expected to continue its upward trajectory.

Data coverage:

The data encompasses B2C enterprises. Figures are based on offline and online spending by consumers, including VAT. Not included are B2B and B2G sales, or other pharmaceutical sales through hospitals or retail stores such as supermarkets.

Modeling approach:

Market sizes are determined through a bottom-up approach, building on specific predefined factors for each market market. As a basis for evaluating markets, we use industry associations, third-party studies and reports and survey results from our primary research (e.g., the Statista Global Consumer Survey). In addition, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per country, consumer healthcare spending, GDP and internet penetration. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the relevant market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. For forecasting digital trends such as the online-pharmacy sales share we use exponential trend smoothing and the s-curve method. The main drivers are healthcare expenditure per country and consumer healthcare spending.

Additional notes:

The data is modeled using current exchange rates. The impact of the COVID-19 pandemic and the Russia-Ukraine war are considered at a country-specific level. The market is updated twice a year. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global online pharmacy sector was estimated at 32 billion U.S. dollars by the end of 2023. In the United States, forecasts indicate that this figure would reach approximately 5.7 billion, solidifying its position as one of the largest online pharmacy markets. However, China dominates the pharma e-commerce industry worldwide, generating nearly 8.5 billion dollars in revenue. With China at the forefront, it is no wonder digital pharmacies make up the fastest-growing segment in the Asian digital health market.